Deutsche Bank analyst Gregg Gilbert believes the upcoming Phase III read-outs for JZP-110 could "stimulate" shares of Jazz Pharmaceuticals. JAZZ expects the Phase III studies of JZP-110 to read out in Q1 for obstructive sleep apnea and Q2 for narcolepsy. JZP-110 is one of the company's most important pipeline assets given its "strong clinical profile, large market, and unmet need," Gilbert tells investors in a research note. His thesis on Jazz assumes that the Phase III studies are successful and that JZP-110 gets to market in 2018. The analyst believes his year-five sales estimate of $400M could prove conservative. Gilbert keeps a Buy rating on Jazz with a $148 price target.